Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Reexamination Certificate
2008-04-22
2008-04-22
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
C424S234100, C424S248100, C424S278100, C424S282100, C435S004000, C435S041000, C435S071100, C435S325000, C435S363000, C435S366000, C435S372000
Reexamination Certificate
active
07361348
ABSTRACT:
The invention concerns immunogenic glycopeptides derived from pathogenic microorganisms, useful for vaccination and diagnosis of infections caused by said pathogenic microorganisms (bacteria or fungi), and methods for selecting them and preparing them. Said glycopeptides are selected in the group consisting of: a1) glycopeptides essentially consisting of a glycosylated T epitope, comprising 14 to 25 amino acids, among which at least a neutral amino acid is bound to a di- or to a trisaccharide (glycoside linkage) and at least 15% among said amino acids are proline, one of the proline being located in position −1 to −4, relative to the position of said neutral amino acid, which glycopeptides are: exhibited by a class II MHC molecule, specifically identified by T CD+4 lymphocytes induced by immunisation with the native glycopeptide from which they are derived, but are not identified by the T CD+4 lymphocytes induced by immunisation with a non-glycosylated peptide of same sequence and capable of inducing a proliferation of said T CD+4 lymphocytes by which they are identified and the secretion of cytokines by said lymphocytes and b1) glycopeptides having a sequence of 15 to 39 amino acids including the sequence of the glycopeptide as defined in a1), excluding the glycopeptide of sequence SEQ ID NO:11.
REFERENCES:
patent: 5714593 (1998-02-01), Laqueyrerie et al.
patent: 2004/0142453 (2004-07-01), Laqueyrerie et al.
patent: 98 16646 (1998-04-01), None
patent: 98 29132 (1998-07-01), None
Karen M. Dobos et al.: “Definition of the full extent of glycosylation of the 45-kilodalton glycoprotein ofMycobacterium tuberculosis” Journal of Bacteriology, vol. 178, No. 9 pp. 2498-2506, 1996.
Henriku Franzyk et al: “Synthesis of aliphatic O-dimannosyl amino acid building blocks for solid-phase assembly of glycopeptide libraries” J Chem Soc Perkin Trans 1, vol. 22, pp. 2883-2898, 1995.
Felix Romain et al.: “Deglyscosylation of the 45/47-kilodalton antigen complex ofMycobacterium tuberculosisdecreases its capacity of elicit in vivo or in vitro cellular immune responses” Infection and Immunity, vol. 67, No. 11, pp. 5567-5572, Nov. 1999.
Marchal Gilles
Pescher Pascale
Romain Felix
Institut Pasteur
Oblon & Spivak, McClelland, Maier & Neustadt P.C.
Swartz Rodney P
LandOfFree
Immunogenic glycopeptides, screening, preparation and uses does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic glycopeptides, screening, preparation and uses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic glycopeptides, screening, preparation and uses will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2759171